Glaukos (GKOS) is down -8.5%, or -$9.38 to $100.85.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS:
- Video: Wells Fargo dips as big bank earnings continue
- Maintaining a Buy on Glaukos: Near‑Term iDose Reset but Strong Core Business and Epioxa-Driven Long‑Term Upside
- Closing Bell Movers: Glaukos slips 13% after pre-announcement
- Glaukos: Solid Fundamentals, Strong Multi-Segment Growth, and iDose Trajectory Support a Buy Rating Despite Near-Term Volatility
- Glaukos Reports Strong Preliminary Q4 and 2025 Sales Growth